About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Innovative Science
We are passionate and committed to developing new therapies that can provide transformative clinical benefit to patients. Our late-stage product candidate voxelotor (GBT440) is an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen and is in clinical development for the treatment of sickle cell disease.
Latest News
05-16-19 GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program05-08-19 GBT Reports Recent Business Progress and First Quarter 2019 Financial Results05-06-19 GBT Announces New Employment Inducement Grants
more news »